In the BioHarmony Drug Report Database

"Preview" Icon

Tenapanor

Ibsrela (tenapanor) is a small molecule pharmaceutical. Tenapanor was first approved as Ibsrela on 2019-09-12. It is used to treat irritable bowel syndrome in the USA. It is known to target sodium/hydrogen exchanger 3. Ibsrela’s patents are valid until 2030-05-02 (FDA).

 

Trade Name

 

Ibsrela
 

Common Name

 

tenapanor
 

ChEMBL ID

 

CHEMBL3304485
 

Indication

 

irritable bowel syndrome
 

Drug Class

 

Sodium-hydrogen antiporter inhibitors

Image (chem structure or protein)

Tenapanor structure rendering